---
url: https://www.npr.org/sections/shots-health-news/2025/11/21/nx-s1-5615168/glp-1-weight-loss-drugs-brain-nausea-wegovy-ozempic
title: Brain scientists are seeking weight-loss drugs without the nausea
publisher: npr
usage: rejected
initial_rank: 5
---
## Article summary
Brain scientists are investigating ways to mitigate the nausea and other side effects associated with popular weight-loss drugs like Wegovy and Zepbound. These GLP-1 agonist drugs mimic a hormone to reduce appetite and slow digestion, but their impact on the brain's "vomit center" causes significant queasiness for many users. Researchers are exploring methods to target the appetite-suppressing effects of these drugs while avoiding the nausea-inducing pathways. One approach involves directing the drug away from the vomit center and towards the area that signals fullness, though separating these effects has proven challenging. Another strategy combines a low dose of GLP-1 drugs with oxytocin, an appetite suppressant, to achieve weight loss without sickness in rats. Beyond nausea, these drugs can also decrease thirst, posing a dehydration risk. Scientists have identified specific brain areas influenced by GLP-1 that affect thirst, potentially allowing for the development of drugs that preserve hydration signals. Furthermore, GLP-1 drugs appear to target a brain region involved in addiction and reward, reducing cravings for highly palatable foods and potentially offering new avenues for treating substance use disorders. This research aims to refine GLP-1 therapies to maximize weight-loss benefits while minimizing unpleasant and potentially dangerous side effects.
